Trials / Completed
CompletedNCT00065312
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | naveglitazar |
Timeline
- First posted
- 2003-07-22
- Last updated
- 2006-07-19
Locations
42 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00065312. Inclusion in this directory is not an endorsement.